HK Stock Market Move | CARSGEN-B (02171) Increase by over 6%, Kaili Me research results will be presented in a poster presentation at the 2026 ESMO Annual Meeting.

CARSGEN-B (02171) rose by more than 6%, as of press time, it rose by 5.94% to 16.42 Hong Kong dollars, with a turnover of 32.6285 million Hong Kong dollars. On the news front, on July 15th, according to the official WeChat account of Koji Medicine, the company announced that Kailimei (SHR-1210 injection, product number: CT041, a self CAR-T cell therapy candidate targeting Claudin18.2) has initiated a clinical trial for postoperative adjuvant therapy and consolidation therapy for gastric/esophageal adenocarcinoma at the junction of gastroesophageal junction initiated by investigators in China (CT041-CG4010, NCT06857786). The preliminary positive results have been accepted for poster presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting. The abstract will be published on the ESMO website on October 19, 2026, Central European Summer Time (CEST) 00:05. Koji Medicine stated that as of July 15, since the initiation of enrollment in May 2025, all participants receiving Kailimei treatment have not experienced recurrence or metastasis of gastric cancer after surgery. Kailimei is a globally first-in-class self CAR-T cell therapy product targeting Claudin18.2 protein, used for the treatment of Claudin18.2-positive solid tumors. Kailimei was approved by the National Medical Products Administration in June 2026 for the treatment of advanced gastric/esophageal junction adenocarcinoma (G/GEJA) that is Claudin18.2-positive and human epidermal growth factor receptor 2 (HER2) negative, and has failed at least second-line treatment, becoming the first entity in the world to receive approval for the marketing of CAR-T cell therapy for solid tumors.